Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization: Anixa Biosciences Inc (ANIX)

Anixa Biosciences, Inc. (ANIX) is exposed to risks stemming from the instability of global chemical supplies and the complexity of protecting patents abroad. The company is establishing a scientific center, integrating diagnostics with the development of vaccines for women's health. The verified price history on the GURU.Markets chart reflects an EV/EBITDA of 0.00. Future growth relies on grants, collaboration with the Cleveland Clinic, and FDA approval.

For Anixa Biosciences, Inc. (ANIX), operating in the high-risk biopharmaceutical sector, this indicator serves as a filter for assessing business value relative to operational efficiency. The Enterprise Value to EBITDA multiple compares the company's total market value with its earnings before interest, taxes, depreciation, and amortization. The trend in the Enterprise Value to EBITDA multiple helps identify asset overheating in the absence of stable revenue. This is critically important for minimizing risks when investing in early-stage clinical developments.